Common Contracts
5 similar null contracts by Sintx Technologies, Inc., Adamis Pharmaceuticals Corp, Dolphin Entertainment, Inc.
CONFIDENTIAL July 16, 2020 Dr. B. Sonny Bal, M.D., Ph.D. Chairman, Chief Executive Officer & President SINTX Technologies, Inc.Sintx Technologies, Inc. • July 20th, 2020 • Surgical & medical instruments & apparatus • New York
CONFIDENTIAL June 26, 2020 Dr. B. Sonny Bal, M.D., Ph.D. Chairman, Chief Executive Officer & President SINTX Technologies, Inc.Sintx Technologies, Inc. • June 30th, 2020 • Surgical & medical instruments & apparatus • New York
CONFIDENTIAL June 23, 2020Sintx Technologies, Inc. • June 24th, 2020 • Surgical & medical instruments & apparatus • New York
June 5, 2020 Mr. William O’Dowd IV Chief Executive Officer Dolphin Entertainment, Inc.Dolphin Entertainment, Inc. • June 9th, 2020 • Services-personal services • New York
Adamis Pharmaceuticals Corporation 8-KAdamis Pharmaceuticals Corp • February 21st, 2020 • Pharmaceutical preparations • New York
This letter (the “Agreement”) constitutes the agreement between Adamis Pharmaceuticals Corporation (the “Company”) and Maxim Group, LLC (“Maxim” or the “Lead Manager”), that Maxim shall serve as the exclusive lead placement agent for the Company, on a “reasonable best efforts” basis ( a “Placement”), in connection with the proposed offerings of shares (the “Shares”) or the “Securities”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) and warrants to purchase shares of Common Stock (the “Warrants” and, together with the Shares, the “Securities”). The terms of such Placement and the Securities shall be mutually agreed upon by the Company and the Lead Manager and, if a Direct Placement, the purchasers (each, a “Purchaser” and collectively, the “Purchasers”) and nothing herein grants Maxim the power or authority to bind the Company or any Purchaser or creates an obligation for the Company to issue any Securities or complete the Placement. This Agreement and
